AbCellera has begun the second phase of expansion at its Vancouver, Canada plant aimed at supporting antibody demand from its biopharma partners.
According to the firm, the 380,000 square-foot site will support AbCellera‚Äôs capabilities to develop antibody-based medicines to the clinic.
‚ÄúWe have already developed a world-leading antibody discovery engine that finds optimal clinical antibody candidates for our partners,‚ÄĚ Murray McCutcheon, senior vice president corporate development at AbCellera told BioProcess Insider.
‚ÄúThe second phase of our expansion will extend those capabilities to include activities that support the development of those antibodies into the clinic, including translational science, process development, and clinical manufacturing. Working together in these facilities will seamlessly integrate our discovery and clinical manufacturing teams as they build intentional workflows that will streamline the development of antibody drug candidates to the clinic.‚ÄĚ
AbCellera also claims it is working to encourage biopharma partners to support programs without needing to build capabilities, infrastructure, and teams. With regard to its ‚Äúlarge biopharma partners,‚ÄĚ the company said its integrated technologies enable programs to be unlocked within a single platform.
‚ÄúToday our capabilities enable our partners to advance their programs from a target to optimal clinical antibody candidates for testing. With our expansion, our capabilities will empower our partners to go from a target to clinical trials. We believe AbCellera will be the only antibody discovery company that can provide partners with an integrated solution for bringing novel medicines from target to clinical trials,‚ÄĚ said McCutcheon.
Over half a billion dollars
McCutcheon told us that by the end of this year, the company will have invested over $500 million into scaling up its capabilities, and it anticipates to more than double this before the end of 2025.
‚ÄúThese investments, which are being made in our technology, our workforce, and our infrastructure, have given us a definitive technology advantage, and have established a new technology curve that is now accelerating.‚ÄĚ
In April 2021, AbCellera broke ground on the first phase of its global headquarters in Vancouver ‚Äď a 170,000 square-foot facility that is being developed in collaboration with Dayhu and occupancy expected to occur late next year.
Directly adjacent to the first facility is a 210,000 square-foot building, which is being developed in a partnership with Beedie and anticipated to be complete in 2025. Furthermore, the two facilities are located a closely to the site of AbCellera‚Äôs planned 130,000-square-foot clinical manufacturing facility, which was announced in June 2021.